


*ABOS Musculoskeletal
Oncology Practice-Profiled
Recertification Examination*

BLUEPRINT



**ABOS
PRACTICE-PROFILED**

EXAMINATIONS

ABOS Musculoskeletal Oncology Practice-Profiled Recertification Examination Blueprint

Table of Contents

General Principles	15%
<i>Biostatistics/Epidemiology</i>	1%
<i>Legal/Ethical/Systems-based Practice</i>	2%
<i>Basic Science Principles</i>	2%
<i>Anatomy and Surgical Approaches</i>	6%
<i>Perioperative Management</i>	4%
Neoplasms	85%
<i>Malignant Bone</i>	22%
<i>Benign Bone</i>	15%
<i>Metastatic Disease</i>	16%
<i>Myeloma, Lymphoma</i>	4%
<i>Benign Soft Tissue</i>	7%
<i>Pseudotumors/Imposters/Other</i>	3%
<i>Malignant Soft Tissue Tumor</i>	16%
<i>Syndromes</i>	2%

ABOS Musculoskeletal Oncology Practice-Profiled Recertification Examination Blueprint

General Principles	15%
Biostatistics/Epidemiology	1%
<ul style="list-style-type: none">• Interpretation of epidemiologic information [Disease prevalence and incidence, implant/disease outcomes (eg, fatality rates), associations (eg, risk factors), health impact (eg, risk differences and ratios), sensitivity, specificity, predictive values]• Study design and interpretation [Types of experimental studies (eg, clinical trials), types of observational studies (eg, cohort, case-control), sampling and sample size, subject selection and exposure allocation (eg, randomization or selection bias)]• Hypothesis testing and statistical interference [Confidence intervals, statistical significance and type I error, statistical power and type II error]	
Legal/Ethical/Systems-based Practice	2%
<ul style="list-style-type: none">• Consent and informed consent to treatment, physician-patient relationship, death and dying, research issues, interactions with other health professionals, cultural competence, physician wellness/burnout, safety, quality, teamwork, cost, value-based care, diversity	
Basic Science Principles	2%
<ul style="list-style-type: none">• Biology (fracture healing, biologics, pharmacology), biomechanics (including gait), inflammatory cascades and coagulation	
Anatomy and Surgical Approaches	6%
<ul style="list-style-type: none">• Anatomy, surgical approaches, and soft-tissue coverage/flaps and grafts	
Perioperative Management	4%
<ul style="list-style-type: none">• Preoperative (infection and medical optimization, including nutrition, smoking cessation, glucose management/diabetes, weight loss, prehabilitation, inflammatory arthritis evaluation and management, and radiation therapy/chemotherapy)• Intraoperative (anesthesia/blocks, blood loss prevention, infection prevention, wound management, complications and safety)• Postoperative (multimodal pain management, rehabilitation, wound management, blood management, discharge disposition, prosthetics, deep vein thrombosis, pulmonary embolism, delirium, coagulopathy, surveillance, complications of endoprostheses, and principles of pediatric limb growth)	

**ABOS Musculoskeletal Oncology Practice-Profiled
Recertification Examination Blueprint**

(continued)

Neoplasms	85%
Malignant Bone	22%
<ul style="list-style-type: none"> • Imaging, staging, biopsy, systemic therapy, local therapy, osteosarcoma, chondrosarcoma, Ewing sarcoma, small round cell sarcoma, chordoma, adamantinoma, management of unplanned procedures 	
Benign Bone	15%
<ul style="list-style-type: none"> • Imaging, biopsy, operative and nonoperative treatment, nonossifying fibromas, cysts, giant cell tumors, osteoid osteoma, osteoblastoma, metabolic bone disease, Langerhans cell histiocytosis, enchondroma 	
Metastatic Disease	16%
<ul style="list-style-type: none"> • Pathologic fractures, prophylactic fixation, nonoperative spine, radiation, bisphosphonates, Denosumab, imaging, evaluation, biopsy 	
Myeloma, Lymphoma	4%
<ul style="list-style-type: none"> • Pathologic fractures, prophylactic fixation, nonoperative spine, radiation, bisphosphonates, Denosumab, imaging, evaluation, biopsy 	
Benign Soft Tissue	7%
<ul style="list-style-type: none"> • Imaging, biopsy, tenosynovial giant cell tumor, arteriovenous malformation, myositis, myxoma, lipoma, nerve sheath tumors, fibromatosis 	
Pseudotumors/Imposters/Other	3%
Malignant Soft Tissue Tumor	16%
<ul style="list-style-type: none"> • Imaging, biopsy, staging, operative treatment, radiation, sarcoma, chemotherapy/targeted therapy, management of unplanned excisions 	
Syndromes	2%
<ul style="list-style-type: none"> • Li Fraumeni, multiple hereditary exostoses, Ollier disease, Maffucci syndrome, McCune-Albright syndrome, neurofibromatosis 	

*no more than 1 spine item